64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
A phase 1/2 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, now recruiting.
Overview
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) is a phase 1/2 interventional study registered as NCT04868604 by Clarity Pharmaceuticals Ltd, with 54 participants planned, started 2021-08-11 and due to reach its primary completion in 2026-09. Interventions recorded: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA.
Similar pages
not linked directly; found by shared links- TrialPositron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Shares Clarity Pharmaceuticals, Prostate cancer and the tag pipeline.
- Trial64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Shares Clarity Pharmaceuticals, Prostate cancer and the tag pipeline.
- TrialPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Shares Prostate cancer and the tag pipeline.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.